skip to Main Content

A Look Back at 2020

  • 31 December 2020

TreatSMA wish you good health and access to treatments in 2021. 2020 was a busy year for us as we continued to fight for access for children and adults to Spinraza, Zolgensma and the EAMS for Risdiplam. We have continued…

Read More

Reassurance over treatments and Brexit

  • 21 December 2020
We have spoken to Roche, Novartis Gene Therapies and Biogen about the continued supply of treatments for Spinal Muscular Atrophy. All three companies have clearly indicated that over the past 2 years they were preparing for various outcomes of Brexit negotiations, including a no deal option. As a result of those preparations there is now a suitable reserve of stock for the treatments and no disruption is foreseen.
Read More
Back To Top